What is the purpose of Everolimus Tablet 5mg?
Everolimus Tablet 5mg is used to treat advanced (late-stage) cancers and noncancerous tumors such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), tuberous sclerosis complex (TSC), and neuroendocrine tumors of the.
Is everolimus a type of chemotherapy?
type of medication:
Everolimus is a chemotherapeutic medication used to treat cancer. This drug is referred to as an “mTOR kinase inhibitor.” (See “How Everolimus Works” below for further information.)
What are the benefits of taking an Everolimus Tablet 5mg tablet?
Angiotensin-converting enzyme (ACE) inhibitors, such as EL 5mg Tablet, belong to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It’s widely used to treat high blood pressure and heart failure after a heart attack. It also lowers your chances of having a heart attack or stroke.
What are the Everolimus Tablet 5mg Evertor side effects?
- EVERTOR 5MG TABLET SIDE EFFECTS
- Appetite loss is common.
- Ulcers in the mouth
- Inflammation in the sinuses. to see more click here
Is it true that Everolimus Tablet 5mg causes weight loss?
Side effects include diarrhea, nausea, vomiting, loss of appetite, weight loss, taste changes, nosebleeds, dry skin, dizziness, and headaches, which are all possible side effects. If any of these adverse effects persist or worsen, call your doctor or pharmacist immediately.
Is it true that Everolimus Tablet 5mg causes hair loss?
Exemestane users frequently experience hair loss. In one study, 15% of patients who took exemestane alone experienced hair loss. In another study, ten percent of women treated for breast cancer with Afinitor plus exemestane experienced hair loss.
Is it true that Everolimus makes you tired?
The following are some of the most common AFINITOR adverse effects: Feeling sluggish or exhausted. I have diarrhea. Arms, hands, feet, ankles, the face, and other body parts may swell. abdominal).
What is the everolimus concentration?
Everolimus should be administered at a trough concentration of 3 to 8 ng/mL, as doses above 3 ng/mL have been linked to a lower risk of rejection, and concentrations over 8 ng/mL have been linked to greater toxicity. Interindividual pharmacokinetic diversity exists with everolimus.